Why Are NAFLD Treatments Failing in Clinical Trials?

Dr Vlad Ratziu, professor of hepatology at the Sorbonne Université, shares his thoughts on why treatments for fatty liver disease continue to fall short, in a conversation with Dr Nancy Reau.

Related Keywords

Rush University Medical Center ,Illinois ,United States ,Paris ,France General ,France ,Chicago ,American , ,Vlad Ratziu ,Sorbonne Universit ,Medical School ,New Guidelines ,Treatment Pathways ,American Association ,Liver Diseases ,Nonalcoholic Fatty Liver Disease ,Vafld ,Biliary Disease ,Allbladder Disease ,Metabolic Syndrome ,Liver ,Liver Disease ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,Fatty Liver ,Teatorrhoeic Hepatosis ,Teatosis Hepatis ,Liver Biopsy ,Clinical Research ,Clinical Trials ,Linical Studies ,Biopsy ,Histology ,Preventive Screening ,Screening ,Cl ,